source
- Eli Lilly's $3.8 B acquisition of AtaiBeckley signals growing confidence in psychedelics for depressionPsychedelics are being touted as a potential solution for patients who still struggle to find lasting relief from existing FDA‑approved psychiatric medicines. The article notes that many individual…
- AbCellera reports striking Phase 2 results for hot-flash treatment, shares jump 31%AbCellera Biologics announced positive Phase 2 data for its neurokinin-3 receptor antagonist aimed at relieving vasomotor symptoms such as hot flashes. The company described the results as strikin…